Provided by Tiger Trade Technology Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

49.35
-0.5700-1.14%
Post-market: 49.350.00000.00%19:30 EDT
Volume:937.16K
Turnover:46.19M
Market Cap:3.52B
PE:-15.85
High:50.07
Open:49.75
Low:48.45
Close:49.92
52wk High:94.90
52wk Low:18.26
Shares:71.31M
Float Shares:54.64M
Volume Ratio:1.17
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1128
EPS(LYR):-2.3852
ROE:-20.21%
ROA:-14.95%
PB:2.60
PE(LYR):-20.69

Loading ...

Press Release: Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

Dow Jones
·
Aug 25

Structure Therapeutics CSO Lin Xichen Reports Disposal of Common Shares Worth $207,378.61

Reuters
·
Aug 20

Press Release: Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 11

Advancing Oral GLP‑1 and Amylin Pipeline Supports GPCR Buy Rating with Maintained $70 Price Target

TIPRANKS
·
Aug 08

Structure Therapeutics Chief Commercial Officer John Joseph Berrios Files Initial Beneficial Ownership Statement

Reuters
·
Aug 08

Piper Sandler Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Aug 07

Structure Therapeutics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Structure Therapeutics Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 07

Structure Therapeutics Inc. Q2 Net Income USD -106.159 Million

THOMSON REUTERS
·
Aug 07

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

GlobeNewswire
·
Aug 07

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

GlobeNewswire
·
Aug 03

Structure Therapeutics CSO Lin Xichen Disposes of USD 401,255.43 in Common Shares

Reuters
·
Jul 16

Race to Launch Weight-loss Pills Heats up as Smaller Players Advance

Reuters
·
Jul 08

Trump’s FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?

Macro World​
·
Jul 06

Structure Therapeutics shareholders elect directors at annual meeting

Reuters
·
Jun 19

Why Structure Therapeutics (GPCR) Is Up 13.7% After Phase 2b Obesity Data Hit Nature Medicine And ADA

Simply Wall St.
·
Jun 16

XtalPi Biopharma GPCR Pact Tests AI Drug Discovery And Revenue Potential

Simply Wall St.
·
Jun 14

Nxera Pharma Joins OpenFold AI Consortium to Boost GPCR Drug Discovery

TIPRANKS
·
Jun 10

XtalPi Strikes US$400 Million GPCR Drug Discovery Pact with Global Biopharma Partner

TIPRANKS
·
Jun 09

XTALPI Forges Strategic AI Drug Discovery Alliance Valued Over $400M with Global Pharma Leader for Oral GPCR Therapy

Stock News
·
Jun 09